Chimeric Antigen Receptor (CAR)-T cells with high affinity for their targeted epitopes efficiently kill malignant cells at the expense of excessive and potentially harmful immune activation, while lower-affinity targeting shows a safer profile but compromises tumour cell killing. Here the authors show that the combination of high- and low-affinity CARs results in a T-cell product with maintained functionality while reducing cytokine release and CAR-T-cell exhaustion in mouse models.
- Linda Warmuth
- Sarah Dötsch
- Elvira D’Ippolito